M2 TAMs reduce the anti-tumour activity of T-lymphocytes, causing angiogenesis via vascular endothelial growth factor (VEGF), interaction with CAFs, expression of PD-L1 and activation of the Wnt/β-catenin signalling pathway [46]. Here, VEGFA is linked to neoplasm.